{"id":44326,"date":"2022-05-25T13:01:27","date_gmt":"2022-05-25T11:01:27","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/antibe-therapeutics-appoints-new-board-chair-and-corporate-vice-chairs\/"},"modified":"2022-05-25T13:01:27","modified_gmt":"2022-05-25T11:01:27","slug":"antibe-therapeutics-appoints-new-board-chair-and-corporate-vice-chairs","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/antibe-therapeutics-appoints-new-board-chair-and-corporate-vice-chairs\/","title":{"rendered":"Antibe Therapeutics Appoints New Board Chair and Corporate Vice Chairs"},"content":{"rendered":"
\n

TORONTO–(BUSINESS WIRE)–Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, is pleased to announce the appointment of Robert E. Hoffman, a Director of Antibe, as the new Chair of its Board of Directors. The Company is also creating two corporate Vice Chair positions to recognize the contributions of Walt Macnee, the outgoing Chair, and Dr. John L. Wallace, Chief Scientific Officer and Director since he founded the Company. As Vice Chairs, they will occupy an esteemed corporate position, providing ongoing counsel to the Company on key business initiatives; Antibe is pleased to note that they will both continue to serve on its Board of Directors. Dr. Wallace is also taking the opportunity to return to his vocation as a research scientist, with a continued focus on enriching the Company\u2019s pipeline.\n<\/p>\n

<\/a><\/p>\n

\n\u201cThese changes mark a new era for Antibe,\u201d noted Mr. Macnee, the Company\u2019s outgoing Board Chair. \u201cIn 2013, when John invited me to replace him as Chair, concerns about opioids were just breaching public consciousness. I was excited to join a world-renowned scientist to build a company capable of tackling such a challenge. Today, with otenaproxesul positioned to directly address this crisis, Robert\u2019s background is a perfect fit for Antibe\u2019s ambitions, particularly his experience in the acute pain space and in U.S. capital markets. I\u2019m delighted to pass the baton to Robert and look forward to working with him as we build a leader in anti-inflammatory therapeutics.\u201d\n<\/p>\n

\nA member of Antibe\u2019s Board since late 2020, Robert E. Hoffman is former CFO of Nasdaq-listed Heron Pharmaceuticals, a commercial stage drug developer with a recently approved acute pain drug. During Mr. Hoffman\u2019s tenure, Heron raised more than $650 million and launched its second commercial therapeutic. His career in the biotech sector began in 1997 at Arena Pharmaceuticals, where he rose to become CFO. While at Arena, he was involved with its IPO and financings raising more than $1.5 billion. For 10 years until 2020, Mr. Hoffman was a member of the Small Business Advisory Committee of the Financial Accounting Standards Board (\u201cFASB\u201d). He is currently President, CEO and Chairman of Kintara Therapeutics (Nasdaq) and a member of the boards of ASLAN Pharmaceuticals (Nasdaq) and privately held FibroBiologics.\n<\/p>\n

\nMr. Hoffman observed, \u201cAs their patients wake up in the recovery room, surgeons routinely prescribe an oral analgesic, generally used for home recovery too. Despite the opioid crisis, oral therapeutic alternatives have remained largely unchanged, reflecting a 20-year lack of innovation in this category. I\u2019m excited to work closely with Dan and his team in building shareholder value as otenaproxesul moves closer to market as a best-in-class drug for acute pain.\u201d\n<\/p>\n

\nWith otenaproxesul\u2019s development well in hand, the Company is also seeking to unlock additional value from its discovery pipeline. Antibe is particularly pleased that Dr. Wallace will focus on exploiting the Company\u2019s hydrogen sulfide platform in new disease areas. Beyond underpinning the Company\u2019s pipeline, his discovery of hydrogen sulfide\u2019s crucial anti-inflammatory role has transformed inflammation science.\n<\/p>\n

\nDr. Wallace commented, \u201cI am tremendously appreciative of Walt\u2019s guidance as Antibe has matured into a clinical stage biotech listed on a senior North American exchange. Given the ever-growing need for safer and more effective anti-inflammatory medicines, I am grateful to our team for transforming a pharmacological concept into an opportunity to combat the opioid epidemic \u2013 and for the chance to continue as a scientist developing better medicines for pain and inflammation.\u201d\n<\/p>\n

\nAbout Antibe Therapeutics Inc.
\n
<\/b>Antibe is a clinical stage biotechnology company leveraging its proprietary hydrogen sulfide platform to develop next-generation safer therapies that target inflammation arising from a wide range of medical conditions. The company\u2019s current pipeline includes assets that seek to overcome the gastrointestinal (\u201cGI\u201d) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (\u201cNSAIDs\u201d). Antibe\u2019s lead drug, otenaproxesul, is in clinical development as a safer alternative to opioids and today\u2019s NSAIDs for post-operative pain. Antibe\u2019s second pipeline drug, ATB-352, is being developed for a specialized acute pain indication. The company\u2019s anticipated next target is inflammatory bowel disease (\u201cIBD\u201d), a condition long in need of safer, more effective therapies. Learn more at antibethera.com<\/a>.\n<\/p>\n

\nForward Looking Information
\n
<\/b>This news release includes certain forward-looking statements under applicable securities laws, which may include, but are not limited to, the anticipated scope, timing, duration and completion of certain of the Company\u2019s clinical trial programs and studies and the anticipated timing for seeking market approval for certain of the Company\u2019s drugs and therapies for certain additional indications. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions \u201cwill\u201d, \u201canticipate\u201d, \u201cbelieve\u201d, \u201cplan\u201d, \u201cestimate\u201d, \u201cexpect\u201d, \u201cintend\u201d, \u201cpropose\u201d and similar wording. Forward-looking statements involve known and unknown risks and uncertainties that could cause actual results, performance, or achievements to differ materially from those expressed or implied in this news release. Factors that could cause actual results to differ materially from those anticipated in this news release include, but are not limited to, the Company\u2019s inability to timely execute on its business strategy and timely and successfully compete its clinical trials and studies, the Company\u2019s inability to obtain the necessary regulatory approvals related to its activities, risks associated with drug and medical device development generally and those risk factors set forth in the Company\u2019s public filings made in Canada and available on www.sedar.com<\/a>. The Company assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those reflected in the forward-looking statements except as required by applicable law.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nAntibe Therapeutics Inc.
\n
Christina Cameron
\n
VP Investor Relations
\n
+1 416-577-1443
\n
christina@antibethera.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

TORONTO–(BUSINESS WIRE)–Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, is pleased to announce the appointment of Robert E. Hoffman, a Director of Antibe, as the new Chair of its Board of Directors. The Company is also creating two corporate … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-44326","6":"format-standard","7":"category-industry"},"yoast_head":"\nAntibe Therapeutics Appoints New Board Chair and Corporate Vice Chairs - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/antibe-therapeutics-appoints-new-board-chair-and-corporate-vice-chairs\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Antibe Therapeutics Appoints New Board Chair and Corporate Vice Chairs - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"TORONTO–(BUSINESS WIRE)–Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, is pleased to announce the appointment of Robert E. Hoffman, a Director of Antibe, as the new Chair of its Board of Directors. The Company is also creating two corporate ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/antibe-therapeutics-appoints-new-board-chair-and-corporate-vice-chairs\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-05-25T11:01:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220525005356\/en\/718346\/21\/ANTIBE-logo-RGB.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/antibe-therapeutics-appoints-new-board-chair-and-corporate-vice-chairs\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/antibe-therapeutics-appoints-new-board-chair-and-corporate-vice-chairs\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Antibe Therapeutics Appoints New Board Chair and Corporate Vice Chairs\",\"datePublished\":\"2022-05-25T11:01:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/antibe-therapeutics-appoints-new-board-chair-and-corporate-vice-chairs\\\/\"},\"wordCount\":975,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/antibe-therapeutics-appoints-new-board-chair-and-corporate-vice-chairs\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220525005356\\\/en\\\/718346\\\/21\\\/ANTIBE-logo-RGB.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/antibe-therapeutics-appoints-new-board-chair-and-corporate-vice-chairs\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/antibe-therapeutics-appoints-new-board-chair-and-corporate-vice-chairs\\\/\",\"name\":\"Antibe Therapeutics Appoints New Board Chair and Corporate Vice Chairs - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/antibe-therapeutics-appoints-new-board-chair-and-corporate-vice-chairs\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/antibe-therapeutics-appoints-new-board-chair-and-corporate-vice-chairs\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220525005356\\\/en\\\/718346\\\/21\\\/ANTIBE-logo-RGB.jpg\",\"datePublished\":\"2022-05-25T11:01:27+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/antibe-therapeutics-appoints-new-board-chair-and-corporate-vice-chairs\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/antibe-therapeutics-appoints-new-board-chair-and-corporate-vice-chairs\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/antibe-therapeutics-appoints-new-board-chair-and-corporate-vice-chairs\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220525005356\\\/en\\\/718346\\\/21\\\/ANTIBE-logo-RGB.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220525005356\\\/en\\\/718346\\\/21\\\/ANTIBE-logo-RGB.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/antibe-therapeutics-appoints-new-board-chair-and-corporate-vice-chairs\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Antibe Therapeutics Appoints New Board Chair and Corporate Vice Chairs\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Antibe Therapeutics Appoints New Board Chair and Corporate Vice Chairs - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/antibe-therapeutics-appoints-new-board-chair-and-corporate-vice-chairs\/","og_locale":"en_US","og_type":"article","og_title":"Antibe Therapeutics Appoints New Board Chair and Corporate Vice Chairs - Pharma Trend","og_description":"TORONTO–(BUSINESS WIRE)–Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, is pleased to announce the appointment of Robert E. Hoffman, a Director of Antibe, as the new Chair of its Board of Directors. The Company is also creating two corporate ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/antibe-therapeutics-appoints-new-board-chair-and-corporate-vice-chairs\/","og_site_name":"Pharma Trend","article_published_time":"2022-05-25T11:01:27+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220525005356\/en\/718346\/21\/ANTIBE-logo-RGB.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/antibe-therapeutics-appoints-new-board-chair-and-corporate-vice-chairs\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/antibe-therapeutics-appoints-new-board-chair-and-corporate-vice-chairs\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Antibe Therapeutics Appoints New Board Chair and Corporate Vice Chairs","datePublished":"2022-05-25T11:01:27+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/antibe-therapeutics-appoints-new-board-chair-and-corporate-vice-chairs\/"},"wordCount":975,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/antibe-therapeutics-appoints-new-board-chair-and-corporate-vice-chairs\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220525005356\/en\/718346\/21\/ANTIBE-logo-RGB.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/antibe-therapeutics-appoints-new-board-chair-and-corporate-vice-chairs\/","url":"https:\/\/pharma-trend.com\/en\/antibe-therapeutics-appoints-new-board-chair-and-corporate-vice-chairs\/","name":"Antibe Therapeutics Appoints New Board Chair and Corporate Vice Chairs - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/antibe-therapeutics-appoints-new-board-chair-and-corporate-vice-chairs\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/antibe-therapeutics-appoints-new-board-chair-and-corporate-vice-chairs\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220525005356\/en\/718346\/21\/ANTIBE-logo-RGB.jpg","datePublished":"2022-05-25T11:01:27+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/antibe-therapeutics-appoints-new-board-chair-and-corporate-vice-chairs\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/antibe-therapeutics-appoints-new-board-chair-and-corporate-vice-chairs\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/antibe-therapeutics-appoints-new-board-chair-and-corporate-vice-chairs\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220525005356\/en\/718346\/21\/ANTIBE-logo-RGB.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220525005356\/en\/718346\/21\/ANTIBE-logo-RGB.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/antibe-therapeutics-appoints-new-board-chair-and-corporate-vice-chairs\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Antibe Therapeutics Appoints New Board Chair and Corporate Vice Chairs"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44326","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=44326"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44326\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=44326"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=44326"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=44326"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}